Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studies
Michel Sabé, Adi Sulstarova, Alban Glangetas, Marco De Pieri, Luc Mallet, Logos Curtis, Hélène Richard-Lepouriel, Louise E. Penzenstadler, Federico Seragnoli, Gabriel Thorens, DANIELE FABIO ZULLINO, Katrin H. Preller, Kerem Böge, Stefan Leucht, Christoph Ulrich Correll, Marco Solmi, Stefan Kaiser, Matthias Kirschner
Abstract
BACKGROUND: Persons with schizophrenia are excluded from psychedelic-assisted therapy due to concerns about the risk of triggering or worsening psychosis. However, there is limited meta-analytic data on the risk of psychedelic-induced psychosis in individuals with pre-existing psychotic disorders. METHODS: We conducted a systematic review, meta-analysis, and overview of reviews to assess the incidence of psychedelic-induced psychosis and symptom exacerbation in schizophrenia. Our pre-registered protocol (CRD42023399591) covered: LSD, psilocybin, mescaline, DMT, and MDMA, using data from Embase, PubMed, PsyARTICLES, PsyINFO, and trial registries up to November 2023. A random-effects model was used to calculate psychosis incidence, with standardized assessments of study quality. RESULTS: From 131 publications, we analyzed 14 systematic reviews, 20 reviews, 35 randomized-controlled trials (RCTs), 10 case-control studies, 30 uncontrolled trials (UCTs), and 22 cohort studies, most of which were low quality. Meta-analysis of nine studies showed an incidence of psychedelic-induced psychosis at 0.002% in population studies, 0.2% in UCTs, and 0.6% in RCTs. In UCTs including individuals with schizophrenia, 3.8% developed long-lasting psychotic symptoms. Of those with psychedelic-induced psychosis, 13.1% later developed schizophrenia. Sensitivity analyses confirmed the results. CONCLUSION: In summary, the reviewed evidence suggests that schizophrenia might not be a definite exclusion criterion for clinical trials exploring safety and efficacy of psychedelics for treatment-resistant depression and negative symptoms. However, given the low quality and limited number of studies, more high-quality research is needed, and a conservative approach is recommended until further data is available.
Abstract of "Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studies" by Michel Sabé, Adi Sulstarova, Alban Glangetas et al., https://doi.org/10.1038/s41380-024-02800-5, used under its Creative Commons Attribution license (CC-BY); markup removed, otherwise unmodified.
Record
- Archive ID
- doi:10.1038/s41380-024-02800-5
- Published
- Nov 26, 2024
- Venue
- Molecular Psychiatry
- DOI
- 10.1038/s41380-024-02800-5
- PubMed
- 39592825
- Categories
- Psychedelics and Drug Studies
- License
- cc-by
- Provenance
- openalex